These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19389538)

  • 1. Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin.
    Lin J; Lott JP; Amorosa VK; Kovarik CL
    J Am Acad Dermatol; 2009 May; 60(5):882-3. PubMed ID: 19389538
    [No Abstract]   [Full Text] [Related]  

  • 2. What caused this lingual hyperpigmentation in a patient with chronic hepatitis C?
    Radha Krishna Y; Itha S
    Liver Int; 2010 Mar; 30(3):416. PubMed ID: 19422481
    [No Abstract]   [Full Text] [Related]  

  • 3. A surprising hyperpigmentation of the gums and tongue.
    Dell'Isola S; Ialungo AM; Starnini G; Roselli P; Ghittoni G; Caturelli E
    Gut; 2008 Dec; 57(12):1697, 1727. PubMed ID: 19022927
    [No Abstract]   [Full Text] [Related]  

  • 4. Nonischemic cardiomyopathy related to pegylated interferon and ribavirin.
    Choy-Shan A; Berezovskaya S; Zinn A; Sedlis SP; Bini EJ
    Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1438-40. PubMed ID: 19907230
    [No Abstract]   [Full Text] [Related]  

  • 5. Lingual hyperpigmentation with pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
    Sood A; Midha V; Bansal M; Goyal A; Sharma N
    Indian J Gastroenterol; 2006; 25(6):324. PubMed ID: 17264447
    [No Abstract]   [Full Text] [Related]  

  • 6. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anterior uveitis in a patient treated with pegylated interferon and ribavirin].
    Carneros Martín JA; Fuentes Coronel A; Alvarez Delgado A; González San Martín F
    Med Clin (Barc); 2003 Mar; 120(9):359. PubMed ID: 12646118
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral hyperpigmentation associated with interferon-alpha and ribavirin therapy for hepatitis C virus infection.
    Marcoval J; Notario J; Martín C; Gómez S
    Actas Dermosifiliogr; 2014 Mar; 105(2):211-2. PubMed ID: 23623282
    [No Abstract]   [Full Text] [Related]  

  • 9. Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection.
    Tsilika K; Tran A; Trucchi R; Pop S; Anty R; Cardot-Leccia N; Lacour JP; Ortonne JP; Passeron T
    JAMA Dermatol; 2013 Jun; 149(6):675-7. PubMed ID: 23553009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
    Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK
    Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182
    [No Abstract]   [Full Text] [Related]  

  • 11. Pernicious anemia during peginterferon-alpha2b plus ribavirin therapy for chronic hepatitis C.
    Musialik J; Petelenz M; Błoñska-Fajfrowska B; Hartleb M
    Eur J Gastroenterol Hepatol; 2009 May; 21(5):593-4. PubMed ID: 19194303
    [No Abstract]   [Full Text] [Related]  

  • 12. Tongue hyperpigmentation during interferon therapy.
    Karabay O; Goksugur N; Ogutlu A
    J Dermatol; 2011 Mar; 38(3):290-1. PubMed ID: 21342236
    [No Abstract]   [Full Text] [Related]  

  • 13. Leukocytoclastic vasculitis during pegylated interferon and ribavirin treatment of hepatitis C virus infection.
    Adişen E; Dizbay M; Hizel K; Ilter N
    Indian J Dermatol Venereol Leprol; 2008; 74(1):60-2. PubMed ID: 18187830
    [No Abstract]   [Full Text] [Related]  

  • 14. Peginterferon and ribavirin for hepatitis C.
    Ben Salem C; Hmouda H; Bouraoui K
    N Engl J Med; 2007 Mar; 356(12):1270; author reply 1271. PubMed ID: 17380578
    [No Abstract]   [Full Text] [Related]  

  • 15. Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C.
    Farshidi D; Chiu MW
    J Am Acad Dermatol; 2010 Jan; 62(1):164-165. PubMed ID: 20082904
    [No Abstract]   [Full Text] [Related]  

  • 16. Tongue hyperpigmentation during PEG-interferon-alfa/ribavirin therapy in a non-Caucasian patient with chronic hepatitis C: a case report and review of the literature.
    Mlika RB; Kerkeni N; Marrak H; Fenniche S; Mokhtar I; Debbiche A
    Int J Dermatol; 2013 May; 52(5):643-4. PubMed ID: 23046405
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon.
    Veldt BJ; Schalm SW; Janssen HL
    J Clin Gastroenterol; 2007 Apr; 41(4):432. PubMed ID: 17413616
    [No Abstract]   [Full Text] [Related]  

  • 18. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 19. Vitiligo after combination therapy of pegylated interferon-α-2a, ribavirin and vitamin D in a patient with chronic hepatitis C.
    Oiso N; Sato M; Kawada A
    J Dermatol; 2013 Sep; 40(9):772-3. PubMed ID: 23855823
    [No Abstract]   [Full Text] [Related]  

  • 20. Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C.
    Atug O; Akin H; Yilmaz Y; Sari M; Tozun N
    J Gastrointestin Liver Dis; 2009 Jun; 18(2):256. PubMed ID: 19565068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.